{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:21:18Z","timestamp":1719926478577},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lundbeck LLC"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.yebeh.2016.03.030","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T14:32:20Z","timestamp":1463581940000},"page":"174-180","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry"],"prefix":"10.1016","volume":"60","author":[{"given":"John M.","family":"Pellock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Faught","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod","family":"Foroozan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Sergott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Donald","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yekaterina","family":"Dribinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Torri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feisal","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouko","family":"Isojarvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2016.03.030_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.eye.6701405","article-title":"The natural history of vigabatrin associated visual field defects in patients electing to continue their medication","volume":"19","author":"Best","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0010","first-page":"1694","article-title":"Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies","volume":"314","author":"Backstrom","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0015","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","volume":"5-15","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/NDT.S4488","article-title":"Current trends in the treatment of infantile spasms","volume":"5","author":"Tsao","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0025","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","article-title":"Infantile spasms: a U.S. consensus report","volume":"51","author":"Pellock","year":"2010","journal-title":"Epilepsia"},{"issue":"Suppl. Pt 1","key":"10.1016\/j.yebeh.2016.03.030_bb0030","first-page":"S43","article-title":"Complex partial seizures in children. Clinical manifestations and identification of surgical candidates","volume":"56","author":"Wyllie","year":"1989","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1474-4422(09)70304-7","article-title":"Definition of refractory epilepsy: defining the indefinable?","volume":"9","author":"Kwan","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1528-1157.2000.tb00134.x","article-title":"The potential for vigabatrin-induced intramyelinic edema in humans","volume":"41","author":"Cohen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jnnp.54.5.435","article-title":"Vigabatrin and psychosis","volume":"54","author":"Sander","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0055","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199141060-00007","article-title":"Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control","volume":"41","author":"Grant","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0060","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"Kalviainen","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0065","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","article-title":"Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings","volume":"50","author":"Krauss","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1542\/peds.106.4.838","article-title":"Visual field constriction in children with epilepsy on vigabatrin treatment","volume":"106","author":"Iannetti","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2007-973477","article-title":"Visual field constriction is not limited to children treated with vigabatrin","volume":"30","author":"Wohlrab","year":"1999","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0404.2011.01598.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States","author":"Faught","year":"2011","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0085","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0090","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0095","series-title":"Sabril [package insert]","year":"2013"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.yebeh.2015.12.004","article-title":"Sabril\u00ae registry 5-year results: characteristics of adult patients treated with vigabatrin","volume":"56","author":"Krauss","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0105","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.yebeh.2011.08.034","article-title":"Registry initiated to characterize vision loss associated with vigabatrin therapy","volume":"22","author":"Pellock","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0110","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1212\/WNL.0b013e318259e2cf","article-title":"Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society","volume":"78","author":"Go","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.03.030_bb0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-2431-12-108","article-title":"Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents","volume":"12","author":"Wheless","year":"2012","journal-title":"BMC Pediatr"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016300014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016300014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:58:59Z","timestamp":1668769139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016300014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":23,"alternative-id":["S1525505016300014"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.03.030","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}